Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models), Application, End-User - Global Forecast 2024-2030


Attention: There is an updated edition available for this report.

Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models), Application, End-User - Global Forecast 2024-2030


The Patient-Derived Xenograft/PDX Model Market size was estimated at USD 222.26 million in 2023 and expected to reach USD 253.51 million in 2024, at a CAGR 14.54% to reach USD 574.99 million by 2030.

Global Patient-Derived Xenograft/PDX Model MarketA Patient-Derived Xenograft (PDX) model is an advanced cancer research and drug development tool that directly transplants human tumor tissues or cells into immunodeficient or humanized mice, allowing for the growth and maintenance of the patient's tumor in a living organism. The increasing prevalence of cancer worldwide drives demand for effective therapies, leading to increased investment in research and development activities. However, ethical and regulatory concerns associated with acquiring patient tissue samples and discrepancies between human and mouse physiology restrain the growth of the patient-derived xenograft (PDX) mode. Furthermore, increasing government funding initiatives for cancer research and advancements in molecular characterization techniques are expected to create lucrative opportunities in the future.Regional InsightsThe patient-derived xenograft/PDX model market in the Americas is highly evolving due to supportive government initiatives and the presence of various research institutes that contribute to advancements in this field. Moreover, biotechnology companies in the region are significant in providing PDX services for drug discovery and personalized medicine approaches. In the European Union, EU-funded projects focus on expanding access to PDX models across member countries. The Middle East is witnessing an increasing interest in PDX model research, with initiatives led by organizations and fostering expertise and resources for preclinical cancer model development. Asia-Pacific region’s investment in biomedical research has resulted in a surge of PDX model studies by domestic pharmaceutical companies. The government frameworks in the Asia-Pacific region also support initiatives that promote PDX model research, developing a potential platform for the patient-derived xenograft/PDX model market.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Patient-Derived Xenograft/PDX Model Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Patient-Derived Xenograft/PDX Model Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., Bioduro-Sundia, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience, Envigo RMS, LLC, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera Biolabs, Hera BioLabs Inc., Inotiv, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Merck KGaA, Oncodesign Services, Pharmatest Services Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, Vertiv Group Corp., WuXi AppTec Co., Ltd., and XENTECH.

Market Segmentation & Coverage

This research report categorizes the Patient-Derived Xenograft/PDX Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Mice Models
Rat Models
Tumor Type
Gastrointestinal Tumor Models
Gynecological Tumor Models
Hematological Tumor Models
Respiratory Tumor Models
Urological Tumor Models
Application
Basic Cancer Research
Biomarker Analysis
Preclinical Drug Development
End-User
Academic & Research Institutions
Contract Research Organizations
Pharmaceutical & Biotechnology Companies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Patient-Derived Xenograft/PDX Model Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Patient-Derived Xenograft/PDX Model Market?
3. What are the technology trends and regulatory frameworks in the Patient-Derived Xenograft/PDX Model Market?
4. What is the market share of the leading vendors in the Patient-Derived Xenograft/PDX Model Market?
5. Which modes and strategic moves are suitable for entering the Patient-Derived Xenograft/PDX Model Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Patient-Derived Xenograft/PDX Model Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing demand for personalized medicine
5.1.1.2. Oncology and preclinical development
5.1.1.3. Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
5.1.2. Restraints
5.1.2.1. High cost of personalized PDX model
5.1.3. Opportunities
5.1.3.1. Rising demand for humanized PDX Model
5.1.3.2. Growth in pharma R&D
5.1.4. Challenges
5.1.4.1. Stringent guidelines regarding the ethical use of animals in cancer research
5.2. Market Segmentation Analysis
5.2.1. Type: Extensive use of mouse models in oncology to develop novel therapeutics
5.2.2. Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
5.2.3. Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
5.2.4. End-User: Rising applicability of patient-derived xenografts in academic and research institutes
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Patient-Derived Xenograft/PDX Model Market, by Type
6.1. Introduction
6.2. Mice Models
6.3. Rat Models
7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type
7.1. Introduction
7.2. Gastrointestinal Tumor Models
7.3. Gynecological Tumor Models
7.4. Hematological Tumor Models
7.5. Respiratory Tumor Models
7.6. Urological Tumor Models
8. Patient-Derived Xenograft/PDX Model Market, by Application
8.1. Introduction
8.2. Basic Cancer Research
8.3. Biomarker Analysis
8.4. Preclinical Drug Development
9. Patient-Derived Xenograft/PDX Model Market, by End-User
9.1. Introduction
9.2. Academic & Research Institutions
9.3. Contract Research Organizations
9.4. Pharmaceutical & Biotechnology Companies
10. Americas Patient-Derived Xenograft/PDX Model Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Agreement, Collaboration, & Partnership
13.3.1.1. Kiyatec and Xenostart Formally Announce a Collaborative Agreement to Help Reduce Drug Development Costs by Providing Correlative ex Vivo Efficacy Data Using Kiyatec’s 3D Spheroid Screening Platform, Kiya-Predict
13.3.1.2. Soteria, Certis Partner to Generate Drug Response Predictions Using AI Platform, Mouse Xenografts
13.3.1.3. GemPharmatech and Charles River Laboratories Sign Exclusive Agreement to Distribute Next Generation NCG Portfolio
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abnova Corporation
14.1.2. Altogen Labs
14.1.3. Aragen Life Sciences Pvt. Ltd.
14.1.4. Bioduro-Sundia
14.1.5. BioReperia AB
14.1.6. Champions Oncology, Inc.
14.1.7. Creative Biolabs
14.1.8. Crown Bioscience
14.1.9. Envigo RMS, LLC
14.1.10. EPO Berlin-Buch GmbH
14.1.11. GemPhamatech LLC
14.1.12. Hera Biolabs
14.1.13. Hera BioLabs Inc.
14.1.14. Inotiv, Inc.
14.1.15. InSphero AG
14.1.16. LIDE Shanghai Biotech, Ltd.
14.1.17. Merck KGaA
14.1.18. Oncodesign Services
14.1.19. Pharmatest Services Oy
14.1.20. TheraIndx Lifesciences Pvt. Ltd.
14.1.21. Urosphere SAS
14.1.22. Vertiv Group Corp.
14.1.23. WuXi AppTec Co., Ltd.
14.1.24. XENTECH
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RESEARCH PROCESS
FIGURE 2. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2023 VS 2030
FIGURE 3. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET DYNAMICS
FIGURE 7. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2030 (%)
FIGURE 10. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings